Ion AmpliSeq™ Target Selection Technology
Have a sales rep contact me
about Ion AmpliSeq™ Target Selection Technnology
- Enables interrogation of samples from 10 ng of input DNA including FFPE and FNB
- Selects targets using a single-tube assay generating up to 1536 amplicons
- Employs a 9.5 hr workflow starting from 10 ng of DNA to a list of known and novel variants
- Delivers highly accurate data that detects variants at as low as 5% allele frequency
The Ion AmpliSeq™ Target Selection Technology is ultra-high multiplex PCR amplification-based target selection technology for research use. Part of an end-to-end solution for targeted sequencing, the Ion AmpliSeq™ Target Selection Technology is used with Ion Personal Genome Machine™ (PGM™) sequencers and Torrent Suite Variant Caller plugin software that can detect variants down to as low as the 5% allelic frequency level.
Target selection methods employed by other next-generation system platforms require 250 ng of DNA input, making interrogation of FFPE samples challenging. Ion AmpliSeq™ Target Selection Technology requires 10 ng of DNA input, making economical and efficient sequencing of FFPE for detection of germline or somatic mutations a reality.
The Ion AmpliSeq™ Fixed Content Panels and Custom Solutions Provide Research Flexibility
Coming Soon
- Ion AmpliSeq™ Comprehensive Cancer Panel-- targets about 400 genes implicated in tumor formation and interrogates about ~10,000 amplicons in total, using the Ion 318™ chip.
- Ion AmpliSeq™ Inherited Disease Panel-- focuses on Mendelian disease research, targeting about 100 disease states and enabling scientists to interrogate ~10,000 amplicons in total, using the Ion 316™ chip.
- Ion AmpliSeq™ Designer--web-based software that enables researchers to specify genomic regions, ranging in size from 1 kb to 1 Mb, for assay design and use with the Ion AmpliSeq™ Library Kit to amplify DNA.
Available Now
The Ion AmpliSeq™ Cancer Panel is designed to detect mutations in “hotspot” regions of 46 oncogenes and tumor suppressor genes with an emphasis on KRAS, BRAF, and EGFR genes.
